[Symptomatic management in multiple sclerosis].
Multiple sclerosis is an autoimmune disease, characyerized by demylinization of white matter of Central Nervous System (CNS). Its etiology is still unknown. In the world, about 2.000.000 of people are affected by MS, with higher prevalence in North-America and North-Europe. Two are the essential features of the therapeutical management in MS: 1) immunomodulating therapy, which consists of "disease modifing drugs"; 2) symptomatic treatment. Only some patients can benefit of immunomodulating therapy, whereas symptomatic treatment can be helpfull to everbody. In the following pages the authors will review the medical options used in the diagnostic, prognostic and therapeutic management of MS.
Pappalardo
A
A
Sezione Sclerosi Multipla e Malattie Demielinizzanti, Università degli Studi di Catania, Italia. pange.bel@virgilio.it
Patti
F
F
Restivo
D A
DA
Reggio
A
A
D003680:Deglutition Disorders / Q000209:etiology; D005221:Fatigue / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000209:etiology; D009103:Multiple Sclerosis / Q000150:complications* / Q000175:diagnosis*; D009128:Muscle Spasticity / Q000209:etiology; D009902:Optic Neuritis / Q000209:etiology; D012131:Respiratory Insufficiency / Q000209:etiology; D012735:Sexual Dysfunction, Physiological / Q000209:etiology; D014202:Tremor / Q000209:etiology; D014570:Urologic Diseases / Q000209:etiology